• Chimerix Inc., of Durham, N.C., published results of a Phase II study of brincidofovir (CMX001) for cytomegalovirus (CMV) in hematopoietic cell transplant (HCT) recipients in the Sept. 26, 2013, issue of the New England Journal of Medicine. The drug has shown broad-spectrum antiviral activity against double-stranded DNA viruses, including CMV.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter